Compare Heron Therapeutics Inc (HRTX) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NextEra Energy, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while NextEra Energy, Inc. trades at $77.33 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 2373× Heron Therapeutics Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and NextEra Energy, Inc. for 83 Days on average.
| HRTX | NEE | |
|---|---|---|
Market Cap | $68.01M | $161.39B |
Volume | 1,891,941 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $1.49 | $97.88 |
52-Week Low | $0.27 | $75.49 |
Typical Hold Time | 35 Days | 83 Days |
Enterprise Value | $174.75M | $268.72B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
NextEra Energy (NEE) trades at $77.06, down 1.05% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a 32.4% net income margin and consistent earnings beats in recent quarters, though it missed in Q4 2025. Recent news highlights growth initiatives, including a $22.3 billion energy infrastructure project in Texas announced on September 30, 2026.
The outlook remains positive with a consensus price target of $96.00, implying 25% upside, supported by robust cash flow and profitability. Risks include rising debt levels, with debt-to-asset ratio increasing to 47.6% in 2025, and sensitivity to interest rate changes. Analyst sentiment is bullish with 66.66% buy ratings, but technical weakness near 52-week lows warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
